Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
Baloxavir marboxil, commonly referred to as Baloxavir, is a novel antiviral medication developed for the treatment of influenza. Its molecular formula is C28H34F2N4O5S, and it is registered under CAS number 1793673-99-0. This compound serves as a prodrug that is rapidly converted into its active form, baloxavir acid, within the human body after oral administration. The primary mechanism of action involves the selective inhibition of the cap-dependent endonuclease activity of the influenza virus polymerase acidic (PA) subunit. By blocking this specific enzymatic function, the drug effectively prevents viral RNA transcription and replication, thereby halting the spread of the virus within host cells.
Clinically, baloxavir is indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours. It is particularly valuable due to its single-dose regimen, which significantly improves patient compliance compared to traditional multi-day antiviral therapies like oseltamivir. This convenience makes it an attractive option for both outpatient management and prophylactic use in household contacts of infected individuals. Clinical trials have demonstrated that baloxavir reduces the duration of viral shedding more rapidly than other approved treatments, potentially lowering the risk of transmission to others. Furthermore, studies suggest efficacy against influenza A and B strains, including some that exhibit resistance to neuraminidase inhibitors.
Despite its advantages, the drug is not suitable for all populations, such as pregnant women or children under certain age thresholds without specific medical guidance. As with any pharmaceutical agent, potential side effects include diarrhea, bronchitis, and nasopharyngitis, though these are generally mild. The development of baloxavir marks a significant advancement in antiviral pharmacology by targeting a novel site on the viral polymerase complex, offering a crucial tool in the ongoing battle against seasonal and pandemic influenza outbreaks. Ongoing research continues to evaluate its long-term safety profile and effectiveness against emerging viral variants.